tbuckley/cabot-search huggingface dataset:
The human tissue-resident CCR5 <sup>+</sup> T cell compartment maintains protective and functional properties during inflammation
Authors: Amanda S. Woodward Davis, Hayley N. Roozen, Matthew J. Dufort, Hannah A. DeBerg, Martha A. Delaney, Florian Mair, Jami R. Erickson, Chloe K. Slichter, Julia D. Berkson, Alexis M. Klock, Matthias Mack, Yu Lwo, Alexander Ko, Rhonda M. Brand, Ian McGowan, Peter S. Linsley, Douglas R. Dixon, Martin Prlic
Journal: Science Translational Medicine (2019)

CCR5 is thought to play a central role in orchestrating migration of cells in response to inflammation. CCR5 antagonists can reduce inflammatory disease processes, which has led to an increased interest in using CCR5 antagonists in a wide range of inflammation-driven diseases. Paradoxically, these antagonists appear to function without negatively affecting host immunity at barrier sites. We reasoned that the resolution to this paradox may lie in the CCR5+ T cell populations that permanently reside in tissues. We used a single-cell analysis approach to examine the human CCR5+ T cell compartment in the blood, healthy, and inflamed mucosal tissues to resolve these seemingly contradictory observations. We found that 65% of the CD4 tissue-resident memory T (TRM) cell compartment expressed CCR5. These CCR5+ TRM cells were enriched in and near the epithelial layer and not only limited to TH1-type cells but also contained a large TH17-producing and a stable regulatory T cell population. The CCR5+ TRM compartment was stably maintained even in inflamed tissues including the preservation of TH17 and regulatory T cell populations. Further, using tissues from the CHARM-03 clinical trial, we found that CCR5+ TRM are preserved in human mucosal tissue during treatment with the CCR5 antagonist Maraviroc. Our data suggest that the human CCR5+ TRM compartment is functionally and spatially equipped to maintain barrier immunity even in the absence of CCR5-mediated, de novo T cell recruitment from the periphery.
Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss
Authors: Emily A. Day, Rebecca J. Ford, Brennan K. Smith, Pedrum Mohammadi-Shemirani, Marisa R. Morrow, Robert M. Gutgesell, Rachel Lu, Amogelang R. Raphenya, Mostafa Kabiri, Andrew G. McArthur, Natalia McInnes, Sibylle Hess, Guillaume Paré, Hertzel C. Gerstein, Gregory R. Steinberg
Journal: Nature Metabolism (2019)
First Results from a Collaborative Initiative To Develop an International Scale for the Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors.
Authors: Susan Branford, Nicholas C.P. Cross, Andreas Hochhaus, Jerald Radich, Giuseppe Saglio, D.W. Kim, Linda Fletcher, Y.L. Wang, Melinda Higgins, Serge Kovalenko, Lee-Yung Shih, J.L. Tang, Edmond Ma, Michael Wong, Jorge Cortes, Dan Jones, Kevin Lynch, John M. Goldman, Timothy Hughes
Journal: Blood (2006)
Ex Vivo Blockade of NF-[dappa]B Signaling in Alloreactive T Cells Prevents Murine Graft-Versus-Host Disease (GVHD).
Authors: Matthew J. O’Shaughnessy, Christine Vogtenhuber, Jonathon S. Serody, Raquel Sitcheran, Albert S. Baldwin, Lenny Dang, Bruce Jaffee, Bruce R. Blazar
Journal: Blood (2004)
Enhanced NK Cell Activation, Cytotoxicity and Ex-Vivo Expansion (EvE) of Cryopreserved Cord Blood (CB) Natural Killer (NK) Cells: Potential Role for CB NK Cells in Adoptive Cellular Immunotherapy (ACI).
Authors: Janet Ayello, Julia Nemiroff, Prakash Satwani, Carmella van de Ven, Evan Shereck, Whitney Lomerzow, Ronald Wapner, Laxmi Baxi, Mitchell S. Cairo
Journal: Blood (2006)
Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).
Authors: Kirk R. Schultz, Jeanette Pullen, Harland Sather, Jonathan Shuster, Michael J. Borowitz, Nyla A. Heerema, Andrew J. Carroll, Paul S. Gaynon, Bruce M. Camitta
Journal: Blood (2004)
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial
Authors: Michael Lübbert, Olga Grishina, Claudia Schmoor, Richard F. Schlenk, Edgar Jost, Martina Crysandt, Michael Heuser, Felicitas Thol, Helmut R. Salih, Marcus M. Schittenhelm, Ulrich Germing, Andrea Kuendgen, Katharina S. Götze, Hans-Walter Lindemann, Carsten Müller-Tidow, Gerhard Heil, Sebastian Scholl, Gesine Bug, Carsten Schwaenen, Aristoteles Giagounidis, Andreas Neubauer, Jürgen Krauter, Wolfram Brugger, Maike De Wit, Ralph Wäsch, Heiko Becker, Annette M. May, Justus Duyster, Konstanze Döhner, Arnold Ganser, Björn Hackanson, Hartmut Döhner
Journal: Journal of Clinical Oncology (2019)

DNA-hypomethylating agents are studied in combination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in myeloid neoplasias. A randomized, phase II trial with a 2 × 2 factorial design was conducted to investigate the effects of the histone deacetylase inhibitor valproate and all-trans retinoic acid (ATRA) in treatment-naive elderly patients with acute myeloid leukemia (AML).Two hundred patients (median age, 76 years; range, 61-92 years) ineligible for induction chemotherapy received decitabine (20 mg/m2 intravenously, days 1 to 5) alone (n = 47) or in combination with valproate (n = 57), ATRA (n = 46), or valproate + ATRA (n = 50). The primary endpoint was objective response, defined as complete and partial remission, tested at a one-sided significance level of α = .10. Key secondary endpoints were overall survival, event-free survival, and progression-free survival and safety.The addition of ATRA resulted in a higher remission rate (21.9% with ATRA v 13.5% without ATRA; odds ratio, 1.80; 95% CI, 0.86 to 3.79; one-sided P = .06). For valproate, no effect was observed (17.8% with valproate v 17.2% without valproate; odds ratio, 1.06; 95% CI, 0.51 to 2.21; one-sided P = .44). Median overall survival was 8.2 months with ATRA v 5.1 months without ATRA (hazard ratio, 0.65; 95% CI, 0.48 to 0.89; two-sided P = .006). Improved survival was observed across risk groups, including patients with adverse cytogenetics, and was associated with longer response duration. With valproate, no survival difference was observed. Toxicities were predominantly hematologic, without relevant differences between the 4 arms.The addition of ATRA to decitabine resulted in a higher remission rate and a clinically meaningful survival extension in these patients with difficult-to-treat disease, without added toxicity.
乳腺癌史妇女的妊娠：妊娠对生存期的影响及最佳受孕时间均无定论，因此个体化考虑是基点
Authors: Emily, Banks, Gillian, Reeves, 郑敏哲（译）, 曹杨（译）, 潘凌亚（校）
Journal: BMJ (2007)

如果年轻女性在生育之前被诊断患乳腺癌，她们会面临对未来生育的艰难抉择。有效的治疗手段往往会降低生育能力，而妊娠对生存率的影响尚无法确知。对于那些确实想妊娠的妇女，如何选择最佳受孕时机仍属未知。
Antibiotic Exposures and Dietary Intakes Are Associated with Changes in Microbiota Compositions in Allogeneic Hematopoietic Stem Cell Transplant Patients
Authors: Chi L. Nguyen, Antonio L.C. Gomes, Jonathan U. Peled, John B. Slingerland, Ann E. Slingerland, Marissa L. Buchan, Peter A. Adintori, Kate A Markey, Annelie Clurman, Molly A. Maloy, Sergio A. Giralt, Miguel-Angel Perales, Ying Taur, Xavier B. Joao, Eric G. Pamer, Marcel R.M. van den Brink
Journal: Blood (2019)
Targeted Disruption of GAS6-Mertk Pathway Leads to Defects in Physiological Clearance of Expelled Nuclei from Erythroblasts by Bone Marrow Macrophages.
Authors: Linda Kadi, Laurent Burnier, Rocco Sugamele, Peter Carmeliet, Greg Lemke, H. Shelton Earp, Glenn K. Matsushima, Marc Schapira, Anne Angelillo-Scherrer
Journal: Blood (2007)
Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning in Patients with Relapsed or Refractory Acute Myeloid Leukemia - Results of a Phase I/II Trial.
Authors: Martin Bornhaeuser, Thomas Illmer, Platzbecker Uwe, Ordemann Rainer, Schetelig Johannes, Schaich Markus, Kiani Alexander, Schuler Ulrich, Ehninger Gerhard
Journal: Blood (2007)
Lentigo maligna melanoma mapping using reflectance confocal microscopy correlates with staged excision: A prospective study
Authors: Cristian Navarrete-Dechent, Miguel Cordova, Saud Aleissa, Konstantinos Liopyris, Stephen W. Dusza, Kivanc Kose, Klaus J. Busam, Travis Hollman, Cecilia Lezcano, Melissa Pulitzer, Chih-Shan J. Chen, Erica H. Lee, Anthony M. Rossi, Kishwer S. Nehal
Journal: Journal of the American Academy of Dermatology (2019)
Prognostic Evaluation of Myelodysplastic Syndromes (MDS): Analysis of Deaths Due to Age-Related Causes.
Authors: Flavia Salvi, Daniela Gioia, Simona Gatto, Margherita Bonferroni, Gianni Cametti, Elisabetta Campa, Cristina Ceretto, Daniela Cilloni, Antonella Darbesio, Stefano D’Ardia, Chiara Maria Dellacasa, Dario Ferrero, Francesca Ficara, Silvia Franceschetti, Roberto Freilone, Filippo Marmont, Enzo Scassa, Anna Tonso, Mario Boccadoro, Gianluca Gaidano, Andrea Gallamini, Eugenio Gallo, Mauro Girotto, Carlo Marinone, Giuseppe Saglio, Alessandro Levis
Journal: Blood (2005)
Clinical and Electrophysiological Characteristics of Sustained Ventricular Tachycardia Occurring 3 to 21 Days After Acute Myocardial Infarction.
Authors: Tetsuro Emori, Tohru Ohe, Kazuo Haze, Katsuro Shimomura
Journal: Circulation (1995)

Patients with sustained ventricular tachycardia (VT) in the post-infarction period, especially more than 48 h after acute myocardial infarction (AMI), have a high mortality. However, clinical characteristics of these patients are unknown, since previous studies have not clarified the relationship between sustained VT and acute myocardial damage. To clarify the prognostic factors in patients with sustained VT in the early post-infarction period, we retrospectively surveyed 961 consecutive patients with AMI. Eleven patients (9 men and 2 women, aged 54 to 80 years) who had no previous myocardial infarction had at least one documented episode of sustained VT between 3 and 21 days after AMI. Late potentials were detected in 7 of 7 patients who underwent signal-averaged electrocardiography within 2 days after the first occurrence of VT. Entrainment was seen in 2 patients. The 5 patients who died in hospital had the following clinical characteristics: 1) cardiogenic shock, 2) extensive infarction, 3) a short interval from AMI to the onset of VT (mean +/- SD: 4 +/- 2 days), and 4) recurrent and refractory VT. In contrast, the 6 patients who survived had the following clinical characteristics: 1) no cardiogenic shock, 2) a relatively late occurrence of VT (mean = SD: 14 +/- 7 days), 3) few episodes of VT, and 4) no recurrence of VT during the follow-up period of 12 to 58 months. The occurrence of sustained VT within 3 weeks after AMI was influenced by the general condition of the patient, and the prognosis was mainly related to cardiac function.
Kidney Function Decline among Black Patients with Sickle Cell Trait and Sickle Cell Disease: An Observational Cohort Study
Authors: Kabir O. Olaniran, Andrew S. Allegretti, Sophia H. Zhao, Maureen M. Achebe, Nwamaka D. Eneanya, Ravi I. Thadhani, Sagar U. Nigwekar, Sahir Kalim
Journal: Journal of the American Society of Nephrology (2019)

Significance Statement Although sickle cell trait and sickle cell disease are associated with CKD among black people in the United States, longitudinal data on GFR decline in such individuals is sparse. In a cohort of black patients having sickle cell trait and sickle cell disease was associated with a significantly faster annual eGFR decline, and eGFR declined significantly faster in patients with sickle cell disease than in those with sickle cell trait. Male sex, diabetes mellitus, and high baseline GFRs were associated with faster eGFR decline in both phenotypes. In sickle cell trait, high hemoglobin S and elevated hemoglobins F and A 2 were associated with a slower eGFR decline. Physicians caring for black patients need to consider sickle cell trait and sickle cell disease status and interactions with comorbidities when evaluating CKD risk. Background Sickle cell trait and sickle cell disease are thought to be independent risk factors for CKD, but the trajectory and predictors of kidney function decline in patients with these phenotypes are not well understood. Methods Our multicenter, observational study used registry data (collected January 2005 through June 2018) and included adult black patients with sickle cell trait or disease (exposures) or normal hemoglobin phenotype (reference) status (ascertained by electrophoresis) and at least 1 year of follow-up and three eGFR values. We used linear mixed models to evaluate the difference in the mean change in eGFR per year. Results We identified 1251 patients with sickle cell trait, 230 with sickle cell disease, and 8729 reference patients, with a median follow-up of 8 years. After adjustment, eGFR declined significantly faster in patients with sickle cell trait or sickle cell disease compared with reference patients; it also declined significantly faster in patients with sickle cell disease than in patients with sickle cell trait. Male sex, diabetes mellitus, and baseline eGFR ≥90 ml/min per 1.73 m 2 were associated with faster eGFR decline for both phenotypes. In sickle cell trait, low hemoglobin S and elevated hemoglobin A were associated with faster eGFR decline, but elevated hemoglobins F and A 2 were renoprotective. Conclusions Sickle cell trait and disease are associated with faster eGFR decline in black patients, with faster decline in sickle cell disease. Low hemoglobin S was associated with faster eGFR decline in sickle cell trait but may be confounded by concurrent hemoglobinopathies. Prospective and mechanistic studies are needed to develop best practices to attenuate eGFR decline in such patients.
Is category specificity in the world or in the mind?
Authors: H. Clark Barrett
Journal: Behavioral and Brain Sciences (2001)

HIT produces category-specific deficits without category- specific mechanisms by assuming that differences in properties of objects are transparently converted into differences in representational format. A complete model would specify the mechanisms that accomplish this. Such category-specific mechanisms may have evolved because assumptions about the properties of some kinds of objects (e.g., living things) are invalid for others (e.g., artifacts).
Epinephrine Infusion in Man
Authors: STEPHEN H. SALZMAN, STEVEN WOLFSON, BRUCE JACKSON, ELIOT SCHECHTER
Journal: Circulation (1971)

A standard test was designed for measurement of the effect of epinephrine infusion on systolic time intervals in 14 normal subjects as a dose-response phenomenon. In order that we might examine the sensitivity of the test, it was applied in nine patients with idiopathic hypertrophic subaortic stenosis. Normal subjects had a characteristic response—a progressive shortening of the duration of electromechanical systole, left ventricular ejection time, and pre-ejection period. Their left ventricular ejection time, corrected for heart rate, did not change. Patients with idiopathic hypertrophic subaortic stenosis responded to epinephrine infusion with paradoxical lengthening of their left ventricular ejection time, corrected for heart rate. After beta blockade (with propranolol), reinfusion of epinephrine shortened the left ventricular ejection time, corrected for heart rate, to normal levels.
Intraspinal Infusion of Bone Marrow Mononuclear Cells to Treat Amyothrophyc Lateral Sclerosis, Results of a Controlled Phase I-II Study
Authors: Miguel Blanquer, Francisca Iniesta, Miguel Angel Perez-Espejo, Jose Meca, Joaquín Gómez Espuch, Ramón Villaverde, Virginia Izura, Francisco Jose Ruiz, Patricia Bleda, Carmen Antunez, Rafael Carles, Joaquin Hernandez, Jose Maria Santos, Maria Juliana Majado, Jose Maria Moraleda
Journal: Blood (2008)
Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS
Authors: Shruti Chaturvedi, Evan M. Braunstein, Xuan Yuan, Jia Yu, Alice Alexander, Hang Chen, Eleni Gavriilaki, Ravi Alluri, Michael B. Streiff, Michelle Petri, Mark A. Crowther, Keith R. McCrae, Robert A. Brodsky
Journal: Blood (2019)
Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
Authors: Hitendra Patel, Ryosuke Okamura, Paul Fanta, Charmi Patel, Richard B. Lanman, Victoria M. Raymond, Shumei Kato, Razelle Kurzrock
Journal: Journal of Hematology & Oncology (2019)

Treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation sequencing technologies. Herein, we investigated the clinical utility of circulating tumor DNA (ctDNA) (the liquid biopsy) in this malignancy.ctDNA was analyzed in 112 patients with PDAC (54-73 genes) and tissue DNA in 66 patients (315 genes) (both clinical-grade next-generation sequencing). Number of alterations, %ctDNA, concordance between ctDNA and tissue DNA, and correlation of ctDNA results with survival were assessed.The most common genes altered in ctDNA were TP53 (46% of patients, N = 51) and KRAS (44%, N = 49). Median number of characterized ctDNA alterations per patient was 1 (range, 0-6), but patients with advanced PDAC had significantly higher numbers of ctDNA alterations than those with surgically resectable disease (median, 2 versus 0.5, P = 0.04). Overall, 75% (70/94) of advanced tumors had ≥ 1 ctDNA alteration. Concordance rate between ctDNA and tissue DNA alterations was 61% for TP53 and 52% for KRAS. Concordance for KRAS alterations between ctDNA and tissue DNA from metastatic sites was significantly higher than between ctDNA and primary tumor DNA (72% vs 39%, P = 0.01). Importantly, higher levels of total %ctDNA were an independent prognostic factor for worse survival (hazard ratio, 4.35; 95% confidence interval, 1.85-10.24 [multivariate, P = 0.001]). A patient with three ctDNA alterations affecting the MEK pathway (GNAS, KRAS, and NF1) attained a response to trametinib monotherapy ongoing at 6 months.Our findings showed that ctDNA often harbored unique alterations some of which may be targetable and that significantly greater numbers of ctDNA alterations occur in advanced versus resectable disease. Furthermore, higher ctDNA levels were a poor prognostic factor for survival.
Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial
Authors: Nora Liebers, Peter-Martin Bruch, Agnes Gambietz, Holly Giles, Junyan Lu, Mareike Knoll, Carolin Kolb, Peter Dreger, Carsten Mueller-Tidow, Wolfgang Huber, Axel Benner, Thorsten Zenz, Sascha Dietrich
Journal: Blood (2019)
Stimulation of the Supportive Function of Marrow Stromal Cells by Anticancer Agents: Critical Role of Marrow Macrophages.
Authors: Kensuke Ohta, Hirohisa Nakamae, Ki-Ryang Koh, Kiyotaka Nakaie, Hong-Zhang Li, Takahisa Yamane, Takayuki Takubo, Masayuki Hino
Journal: Blood (2004)
Lessons From Improv Comedy to Reduce Health Disparities
Authors: Marshall H. Chin
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B‐cell lymphoma
Authors: Lei Qian, Craig Soderquist, April Schrank‐Hacker, Honore Strauser, Vanessa Dupoux, Chi Ngong Tang, Jennifer R. Smith, Ang Sun, Sonali Majumdar, Tran Nguyen, Sandy Widura, Daniel J. Landsburg, Stephen J. Schuster, Richard H. G. Baxter, Agata M. Bogusz
Journal: American Journal of Hematology (2019)

The genetic and molecular abnormalities underlying histological transformation (HT) of nodal marginal zone lymphoma (NMZL) to diffuse large B-cell lymphoma (DLBCL) are not well known. While del(20q12) is commonly deleted in myelodysplastic syndrome it has not previously been associated with DLBCL. We recently described a case of DLBCL harboring del(20q12) in a patient with a history of MZL involving lymph nodes and skin. Here we report eight matched cases of transformed MZL(tMZL): six from nodal MZL (tNMZL) and two from splenic MZL (tSMZL). We found >20% del(20q12) in 4/6 tNMZL, but not in tSMZL, nor in unmatched DLBCL, MZL with increased large cells (MZL-ILC), or MZL cases. To examine whether transformation is associated with a specific gene signature, the matched cases were analyzed for multiplexed gene expression using the Nanostring PanCancer Pathways panel. The differential gene expression signature revealed enrichment of inflammatory markers, as previously observed in MZL. Also, tMZL and de novo DLBCL were enriched for extracellular matrix proteins such as collagen and fibronectin, vascular development protein PDGFRβ, DNA repair protein RAD51, and oncogenic secrete protein Wnt11. A subset of genes is expressed differentially in del(20q12) tMZL cases vs non-del(20q12) tMZL cases. These results suggest a specific pathway is involved in the histological transformation of NMZL, which could serve as an indicator of aggressive clinical course in this otherwise indolent neoplasm.
Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma
Authors: Jessica C. Hochberg, Jaclyn Basso, Liana Klejmont, Lauren Harrison, Allyson M. Flower, Aliza Gardenswartz, Qiuhu Shi, Perry Gerard, Humayan Islam, Mitchell S Cairo
Journal: Blood (2019)
Treatment of Steroid-Resistant Acute GvHD with OKT3 and High-Dose Steroids Versus High-Dose Steroids Alone.
Authors: Stefan Knop, Holger Hebart, Alois Gratwohl, Ernst Holler, Jane F. Apperley, Hans J. Kolb, Dietger Niederwieser, Hermann Einsele
Journal: Blood (2005)